Alliancebernstein L.P. Corvus Pharmaceuticals, Inc. Transaction History

Alliancebernstein L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$3.3 - $4.58 $53,130 - $73,738	-16,100 Closed	0 $0
Q3 2018 Nov 08, 2018	BUY	$8.58 - $11.4 $6,864 - $9,120	800 Added 5.23%	16,100 $138,000
Q2 2018 Aug 13, 2018	BUY	$9.42 - $13.73 $16,014 - $23,341	1,700 Added 12.5%	15,300 $168,000
Q4 2017 Feb 13, 2018	SELL	$9.3 - $16.93 $8,370 - $15,237	-900 Reduced 6.21%	13,600 $141,000
Q3 2017 Nov 13, 2017	BUY	$11.3 - $17.23 $163,850 - $249,835	14,500	14,500 $231,000

30.4M

1.06M

84.3K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $413M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.